Loading...
XSHE002880
Market cap791mUSD
Jan 10, Last price  
25.60CNY
1D
-1.69%
1Q
-3.80%
IPO
39.78%
Name

Shenzhen Weiguang Biological Products Co Ltd

Chart & Performance

D1W1MN
XSHE:002880 chart
P/E
26.55
P/S
5.54
EPS
0.96
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
8.79%
Revenues
1.05b
+56.98%
300,066,443355,210,422452,773,342500,944,346566,136,601623,389,547687,949,170821,469,063904,564,669907,434,715667,931,4621,048,502,589
Net income
219m
+86.06%
71,445,25488,880,568100,541,513124,855,119153,226,959154,749,234156,636,847171,344,660190,398,598205,436,658117,518,018218,651,341
CFO
398m
+33,088.03%
115,880,20020,928,500134,165,948150,089,940126,405,73328,614,44599,540,259185,701,134303,957,547246,886,6011,199,043397,938,765
Dividend
Jul 12, 20240.2 CNY/sh
Earnings
May 16, 2025

Profile

Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human albumin, intravenous immunoglobulin (pH4), freeze-dried intravenous human immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, rabies patient immunoglobulin, tetanus human immunoglobulin, histamine human immunoglobulin, and human fibrinogen, as well as a total of 9 varieties and 21 specifications. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 1985 and is based in Shenzhen, China.
URL
http://www.szwg.com/
IPO date
Jun 16, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,048,503
56.98%
667,931
-26.39%
Cost of revenue
736,594
508,162
Unusual Expense (Income)
NOPBT
311,908
159,770
NOPBT Margin
29.75%
23.92%
Operating Taxes
27,910
16,197
Tax Rate
8.95%
10.14%
NOPAT
283,998
143,573
Net income
218,651
86.06%
117,518
-42.80%
Dividends
(45,360)
Dividend yield
0.63%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
101,402
Long-term debt
515,863
462,280
Deferred revenue
46,775
25,915
Other long-term liabilities
6,051
6,052
Net debt
263,563
2,092
Cash flow
Cash from operating activities
397,939
1,199
CAPEX
Cash from investing activities
Cash from financing activities
447,903
FCF
749,580
(299,784)
Balance
Cash
252,300
294,587
Long term investments
2
267,003
Excess cash
199,875
528,194
Stockholders' equity
1,301,068
1,293,032
Invested Capital
2,398,379
1,904,902
ROIC
13.20%
8.54%
ROCE
11.95%
6.56%
EV
Common stock shares outstanding
226,800
226,800
Price
35.13
10.16%
31.89
-0.14%
Market cap
7,967,484
10.16%
7,232,652
-0.14%
EV
8,262,408
7,261,470
EBITDA
399,217
225,028
EV/EBITDA
20.70
32.27
Interest
15,315
2,057
Interest/NOPBT
4.91%
1.29%